Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HSP90AB1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HSP90AB1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HSP90AB1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HSP90AB1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HSP90AB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HSP90AB1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HSP90AB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HSP90AB1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HSP90AB1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HSP90AB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HSP90AB1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007163421 | Oral cavity | EOLP | regulation of transforming growth factor beta production | 11/2218 | 41/18723 | 6.77e-03 | 3.30e-02 | 11 |
GO:007189722 | Oral cavity | EOLP | DNA biosynthetic process | 33/2218 | 180/18723 | 7.00e-03 | 3.40e-02 | 33 |
GO:000740910 | Oral cavity | EOLP | axonogenesis | 66/2218 | 418/18723 | 8.99e-03 | 4.13e-02 | 66 |
GO:007160421 | Oral cavity | EOLP | transforming growth factor beta production | 11/2218 | 43/18723 | 9.87e-03 | 4.46e-02 | 11 |
GO:004352322 | Oral cavity | EOLP | regulation of neuron apoptotic process | 37/2218 | 212/18723 | 1.00e-02 | 4.52e-02 | 37 |
GO:005189614 | Oral cavity | EOLP | regulation of protein kinase B signaling | 33/2218 | 185/18723 | 1.05e-02 | 4.71e-02 | 33 |
GO:006156414 | Oral cavity | EOLP | axon development | 72/2218 | 467/18723 | 1.14e-02 | 5.00e-02 | 72 |
GO:190332033 | Oral cavity | NEOLP | regulation of protein modification by small protein conjugation or removal | 72/2005 | 242/18723 | 2.44e-16 | 1.61e-13 | 72 |
GO:001603233 | Oral cavity | NEOLP | viral process | 101/2005 | 415/18723 | 1.08e-15 | 5.85e-13 | 101 |
GO:003139633 | Oral cavity | NEOLP | regulation of protein ubiquitination | 62/2005 | 210/18723 | 4.31e-14 | 1.60e-11 | 62 |
GO:004217634 | Oral cavity | NEOLP | regulation of protein catabolic process | 92/2005 | 391/18723 | 1.77e-13 | 5.27e-11 | 92 |
GO:004682231 | Oral cavity | NEOLP | regulation of nucleocytoplasmic transport | 39/2005 | 106/18723 | 1.14e-12 | 2.60e-10 | 39 |
GO:000691331 | Oral cavity | NEOLP | nucleocytoplasmic transport | 75/2005 | 301/18723 | 1.56e-12 | 3.20e-10 | 75 |
GO:005116931 | Oral cavity | NEOLP | nuclear transport | 75/2005 | 301/18723 | 1.56e-12 | 3.20e-10 | 75 |
GO:001905834 | Oral cavity | NEOLP | viral life cycle | 77/2005 | 317/18723 | 3.13e-12 | 5.82e-10 | 77 |
GO:003164733 | Oral cavity | NEOLP | regulation of protein stability | 73/2005 | 298/18723 | 7.46e-12 | 1.17e-09 | 73 |
GO:001049831 | Oral cavity | NEOLP | proteasomal protein catabolic process | 103/2005 | 490/18723 | 1.08e-11 | 1.65e-09 | 103 |
GO:003450432 | Oral cavity | NEOLP | protein localization to nucleus | 71/2005 | 290/18723 | 1.49e-11 | 2.21e-09 | 71 |
GO:007182634 | Oral cavity | NEOLP | ribonucleoprotein complex subunit organization | 60/2005 | 227/18723 | 1.98e-11 | 2.81e-09 | 60 |
GO:005082133 | Oral cavity | NEOLP | protein stabilization | 53/2005 | 191/18723 | 4.09e-11 | 5.41e-09 | 53 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0461220 | Cervix | CC | Antigen processing and presentation | 34/1267 | 78/8465 | 1.06e-09 | 2.14e-08 | 1.26e-08 | 34 |
hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0414120 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0465718 | Cervix | CC | IL-17 signaling pathway | 31/1267 | 94/8465 | 8.71e-06 | 7.43e-05 | 4.39e-05 | 31 |
hsa052157 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa046596 | Cervix | CC | Th17 cell differentiation | 28/1267 | 108/8465 | 1.99e-03 | 7.98e-03 | 4.72e-03 | 28 |
hsa046213 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
hsa05418110 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa04612110 | Cervix | CC | Antigen processing and presentation | 34/1267 | 78/8465 | 1.06e-09 | 2.14e-08 | 1.26e-08 | 34 |
hsa05132110 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa05417110 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa04141110 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa04915110 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0465719 | Cervix | CC | IL-17 signaling pathway | 31/1267 | 94/8465 | 8.71e-06 | 7.43e-05 | 4.39e-05 | 31 |
hsa0521512 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa0465911 | Cervix | CC | Th17 cell differentiation | 28/1267 | 108/8465 | 1.99e-03 | 7.98e-03 | 4.72e-03 | 28 |
hsa0462112 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HSP90AB1 | SNV | Missense_Mutation | | c.1994C>G | p.Ser665Cys | p.S665C | P08238 | protein_coding | deleterious(0.03) | benign(0.078) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HSP90AB1 | SNV | Missense_Mutation | rs756933263 | c.1655N>T | p.Lys552Met | p.K552M | P08238 | protein_coding | deleterious(0.01) | probably_damaging(0.951) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
HSP90AB1 | SNV | Missense_Mutation | | c.1367N>T | p.Arg456Leu | p.R456L | P08238 | protein_coding | deleterious(0) | possibly_damaging(0.906) | TCGA-E2-A1IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
HSP90AB1 | SNV | Missense_Mutation | novel | c.748N>G | p.Ile250Val | p.I250V | P08238 | protein_coding | tolerated(0.42) | benign(0) | TCGA-LL-A7T0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HSP90AB1 | deletion | Frame_Shift_Del | novel | c.217_233delATTGACATCATCCCCAA | p.Ile73ProfsTer19 | p.I73Pfs*19 | P08238 | protein_coding | | | TCGA-A8-A08O-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | PD |
HSP90AB1 | SNV | Missense_Mutation | rs770945397 | c.1346G>A | p.Arg449His | p.R449H | P08238 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HSP90AB1 | SNV | Missense_Mutation | | c.87N>G | p.Ile29Met | p.I29M | P08238 | protein_coding | deleterious(0.01) | possibly_damaging(0.863) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HSP90AB1 | SNV | Missense_Mutation | | c.52N>G | p.Gln18Glu | p.Q18E | P08238 | protein_coding | deleterious(0.02) | possibly_damaging(0.48) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HSP90AB1 | SNV | Missense_Mutation | | c.52N>G | p.Gln18Glu | p.Q18E | P08238 | protein_coding | deleterious(0.02) | possibly_damaging(0.48) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HSP90AB1 | SNV | Missense_Mutation | rs370988754 | c.502C>T | p.Arg168Cys | p.R168C | P08238 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | ZERANOL | ZERANOL | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | ZEARALENONE | ZEARALENONE | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | RADANAMYCIN | RADANAMYCIN | 16464590 |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | GAMBOGIC ACID | GAMBOGIC ACID | 21486005 |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | inhibitor | AUY922 | | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | RHEIN | RHEIN | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | inhibitor | 354702300 | GELDANAMYCIN | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | IPI-504 | RETASPIMYCIN HYDROCHLORIDE | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | MPC-3100 | | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | CELASTROL | CELASTROL | 25756299,21129982 |